drugset / Trial / NCT02298062
Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial
Phase 3
Completed
40 enrolled
Fudan University
Shanghai 10th People's Hospital · collabShanghai 8th People's Hospital · collabShanghai Children's Medical Center · collabShanghai Xuhui Distrct Center Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to investigate the effect of infliximab to the children who don't respond to the first dose of intravenous immunoglobulin (IVIG) (2g/kg) in Kawasaki disease.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-07
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Comparator | intravenous immunoglobulin | Protein / enzyme biologic | 2 g/kg | Intravenous |